KRAS Mutation Lung Cancer: 20 Real Stories

20 stories match lung cancer and KRAS mutation. 18 of them mention chemotherapy.

Cancer Stories

Maureen, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV KRAS Non-Small Cell Lung Cancer: Maureen's Patient Story

Patient Info: Maureen, Female | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: Not reported

Living with KRAS-mutated Stage IV lung cancer after initial Stage I diagnosis, later surgery, and radiation, while remaining active in KRAS and lung cancer advocacy.

Lung Cancer Research Foundation
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Severe blood-clotting disorder, liver injury, and reversible kidney injury during treatment for Stage IV lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 about 1%; KRAS mutation

Metastatic Site: bone (right 4th and 5th ribs)

Restaging before cycle 4 showed a partial response. Cancer treatment was then interrupted as severe acquired iTTP, cholestatic liver injury, and reversible acute kidney injury required intensive management.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lynch-associated lung and colorectal cancers responded to immunotherapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: dMMR/MSI-H pattern with MLH1/PMS2 loss and germline MLH1 mutation; KRAS and PTEN mutations; PD-L1 TPS 15%.

Metastatic Site: right paraspinal metastatic lesion from lung…

After starting iparomlimab plus tuvonralimab, pleural and pelvic disease improved, intestinal wall involvement decreased further after 5 cycles, the paraspinal lung metastasis remained stable, tumor markers stayed normal, and treatment continued.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS/STK11/TP53-mutated lung adenocarcinoma: fatal pembrolizumab-induced myocarditis after adjuvant therapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Ki-67 20-25%; PD-L1 expression 10%; KRAS exon 2 mutation; STK11 mutation; TP53 mutation

As of December 2025, he had died after 15 days of hospitalization from sepsis and multi-organ failure following severe pembrolizumab-induced myocarditis after adjuvant treatment for resected Stage IIIA lung adenocarcinoma.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung adenocarcinoma with paraneoplastic nephrotic syndrome during pembrolizumab therapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >50% by Roche SP263 assay; KRAS exon 3 mutation; NGS/FISH did not identify targets for first-line targeted therapy

Metastatic Site: brain, bone

Pembrolizumab produced partial response and improved nephrotic-syndrome parameters, but bone metastases progressed in September 2022 and the right upper-lobe target lesion progressed 2 months later, leading to carboplatin plus pemetrexed.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed Central
OutcomeCancer-Free / NED
Wyatt, who was diagnosed with Lung CancerLung Cancer

KRAS Lung Cancer: Wyatt's Patient Story

Patient Info: Wyatt, Male

Biomarkers: KRAS mutation mentioned indirectly; exact variant not stated in available source text

Wyatt was living with lung cancer on ongoing chemotherapy and immunotherapy, with multiple prior lines of treatment and significant side effects. As of August 2025, he had tried to access clinical trials but had not enrolled.

The Patient Story
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IVA lung adenosquamous carcinoma: complete response after paclitaxel, nedaplatin, and tislelizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Adenosquamous lung cancer markers; PD-L1 TPS 18%; KRAS, BRAF, PIK3CA, FLT1 mutation; TMB 3.7

Metastatic Site: pleura/chest wall, cervical lymph nodes, axillary…

As of March 30, 2025, he maintained complete response with normal tumor markers, no radiologic evidence of progression or recurrence, and progression-free survival of 46.5 months after paclitaxel/nedaplatin/tislelizumab followed by maintenance tislelizumab.

PubMed Central
OutcomeCancer-Free / NED
Rosemary, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV KRAS Lung Cancer: Rosemary's Patient Story

Patient Info: Rosemary Conway, female, 60s | Stage IV

Biomarkers: KRAS mutation

After 14 months on daraxonracib in a clinical trial, Rosemary’s Stage IV lung cancer had stopped growing and she had returned to walking and lifting weights.

Dana-Farber
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV lung cancer: brain metastasis complete response after chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS-mutated; BRG-1 partial loss; PD-L1 TPS 5%; CPS 20

Metastatic Site: brain (right cerebellar hemisphere)

The right cerebellar brain metastasis completely resolved and chest CT showed only postsurgical changes after carrelizumab plus paclitaxel/carboplatin; immune-mediated adrenal insufficiency improved with systemic glucocorticoids.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Rare lung cancer first discovered as a mass in the skull

Patient Info: Anonymized, Male | Stage IV

Biomarkers: KRAS ; CK7-positive; CDX2-positive; pathology favoured pulmonary enteric adenocarcinoma

Metastatic Site: skull base / sphenoid sinus; right posterior acetabulum

He received palliative radiation and prolonged systemic therapy, completing 35 cycles including 31 maintenance cycles of pemetrexed and pembrolizumab.

PubMed Central
OutcomeNot reported
Terri, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage III KRAS Non-Small Cell Lung Cancer: Terri's Survivor Story

Patient Info: Terri Conneran, Female | Stage III

Biomarkers: KRAS-mutated; PD-L1 level reviewed/tested

As of March 2021, Terri had Stage IIIA KRAS-mutated NSCLC with 3 local recurrences treated over time and had again reached no evidence of disease while continuing close surveillance and advocacy through KRAS Kickers.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Large cell lung carcinoma with solitary jejunal metastasis: no evidence of disease 4 years after treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Primary lung tumor and jejunal metastasis shared a KRAS codon 61 mutation; staining supported lung origin.

Metastatic Site: jejunum

As of January 2010, she was doing well with no evidence of disease 4 years after diagnosis and treatment of a solitary jejunal metastasis from large cell lung carcinoma.

PubMed Central
OutcomeCancer-Free / NED